Login to Your Account



More than so-so progress for Sotio in cancer immunotherapy

By Marie Powers
Staff Writer

Friday, July 18, 2014
newco_news_resized.jpg

The small biotech Sotio AS, of Prague, has shunned the limelight since its founding in 2010. Instead of promoting its potential to treat various forms of cancer, the company is letting its technology do the talking.

Sotio's active cellular immunotherapy-multiple antigen presentation (ACI-MAP) platform is the basis for an oncology product pipeline that uses a patient's activated dendritic cells to induce an immune response that targets particular cancer cells.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription